Canada
· Delayed Price · Currency is CAD Biocure Technology Statistics
Total Valuation
CSE:CURE.X has a market cap or net worth of CAD 365,558. The enterprise value is 397,207.
| Market Cap | 365,558 |
| Enterprise Value | 397,207 |
Important Dates
The last earnings date was Tuesday, April 29, 2025.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:CURE.X has 10.44 million shares outstanding. The number of shares has increased by 1.23% in one year.
| Current Share Class | 10.44M |
| Shares Outstanding | 10.44M |
| Shares Change (YoY) | +1.23% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.66% |
| Owned by Institutions (%) | n/a |
| Float | 93.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.27 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 26.66 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.51 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.04, with a Debt / Equity ratio of 0.04.
| Current Ratio | 0.04 |
| Quick Ratio | 0.04 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -41.20 |
Financial Efficiency
Return on equity (ROE) is -17.83% and return on invested capital (ROIC) is -13.11%.
| Return on Equity (ROE) | -17.83% |
| Return on Assets (ROA) | -10.03% |
| Return on Invested Capital (ROIC) | -13.11% |
| Return on Capital Employed (ROCE) | -22.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.07% in the last 52 weeks. The beta is 2.68, so CSE:CURE.X's price volatility has been higher than the market average.
| Beta (5Y) | 2.68 |
| 52-Week Price Change | -74.07% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 46.50 |
| Average Volume (20 Days) | 6,888 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -318,237 |
| Pretax Income | -262,471 |
| Net Income | -262,471 |
| EBITDA | n/a |
| EBIT | -318,237 |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 17,949 in cash and 49,599 in debt, giving a net cash position of -31,650 or -0.00 per share.
| Cash & Cash Equivalents | 17,949 |
| Total Debt | 49,599 |
| Net Cash | -31,650 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 1.34M |
| Book Value Per Share | 0.13 |
| Working Capital | -575,206 |
Cash Flow
| Operating Cash Flow | 13,714 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:CURE.X does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.23% |
| Shareholder Yield | -1.23% |
| Earnings Yield | -71.80% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 28, 2024. It was a reverse split with a ratio of 0.1111111.
| Last Split Date | Oct 28, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1111111 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |